Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Subcutaneous mastectomy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    15 result(s) found for: Subcutaneous mastectomy. Displaying page 1 of 1.
    EudraCT Number: 2016-005186-31 Sponsor Protocol Number: 01062017 Start Date*: 2018-06-06
    Sponsor Name:Department of Plastic Surgery, Breast and Burns Treatment
    Full Title: Fat Grafting with Ex-Vivo Expanded Adipose-Derived Stem Cells for Breast Reconstruction Following Mastectomy
    Medical condition: This study will include patients with genetic predisposition to development of breast cancer, who are offered prophylactic bilateral skin-sparring mastectomy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10018065 - General disorders and administration site conditions 10071981 BRCA2 gene mutation PT
    20.0 10018065 - General disorders and administration site conditions 10071980 BRCA1 gene mutation PT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-014823-22 Sponsor Protocol Number: LISER-M Start Date*: 2009-07-28
    Sponsor Name:AZIENDA USL DI FORLI`
    Full Title: Second biopsy of axillary sentinel node in the local recurrence of breast cancer after mastectomy and first negative sentinel node. Studio LiSeR - M
    Medical condition: patients with first local recurrence of breast cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-000168-28 Sponsor Protocol Number: IBCSG25-02/BIG3-02 Start Date*: 2005-11-21
    Sponsor Name:International Breast Cancer Study Group (IBCSG)
    Full Title: A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer
    Medical condition: Premenopausal women with histologically proven, resected breast cancer with ER and/or PgR positive tumors
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed) BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003106-16 Sponsor Protocol Number: B2 Start Date*: 2016-08-03
    Sponsor Name:Antonis Valachis
    Full Title: Immunogenicity of influenza vaccination among breast cancer patients treated with trastuzumab in adjuvant setting
    Medical condition: Efficacy of vaccination against influenza in patients with breast cancer treated with Trastuzumab as adjuvant therapy
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000166-13 Sponsor Protocol Number: 24-02 Start Date*: 2005-05-12
    Sponsor Name:International Breast Cancer Study Group (IBCSG)
    Full Title: A phase III trial evaluating the role of ovarian function suppression and the role of exemestane as adjuvant therapies for premenopausal women with endocrine responsive breast cancer.
    Medical condition: Histologically proven, resected breast cancer with ER and/or PgR positive tumors
    Disease: Version SOC Term Classification Code Term Level
    7.0 10057654 LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Prematurely Ended) SE (Completed) DE (Completed) ES (Completed) IE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2016-002846-21 Sponsor Protocol Number: PARENTIDE-02 Start Date*: 2017-04-10
    Sponsor Name:BCN Peptides S.A.
    Full Title: CLINICAL TRIAL PHASE IIa PROOF OF CONCEPT, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED IN PATIENTS WITH NEUROPATHIC PAIN DUE TO PERIPHERAL NERVE INJURY
    Medical condition: Patients with neuropathic pain due to peripheral nerve injury
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004897-32 Sponsor Protocol Number: WO40324 Start Date*: 2018-06-04
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A phase III, randomized, multicenter, open-label, two-arm study to evaluate the pharmacokinetics, efficacy, and safety of subcutaneous administration of the fixed-dose combination of pertuzumab and...
    Medical condition: Human epidermal growth factor receptor 2 (HER2)-positive Early Breast Cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Ongoing) BE (Completed) CZ (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005034-36 Sponsor Protocol Number: KWI-300-104 Start Date*: 2008-07-15
    Sponsor Name:Apotex Inc.
    Full Title: A non comparative, multicentre, repeat dose safety in use study of Neukine® (Filgrastim) in patients receiving chemotherapy known to induce neutropenia
    Medical condition: Febrile neutropenia in breast cancer patients undergoing TAC chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10016288 Febrile neutropenia LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) AT (Completed) PL (Completed) BG (Completed) GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-005544-17 Sponsor Protocol Number: EMR 200038-010 Start Date*: 2009-08-20
    Sponsor Name:Merck KGaA
    Full Title: A randomized, double-blind, controlled phase III study of Stimuvax® (L-BLP25 or BLP25 liposome vaccine) in combination with hormonal treatment versus hormonal treatment alone for first-line therapy...
    Medical condition: post-menopausal women with estrogen receptor (ER)-positive and/or progesterone receptor (PgR)-positive, inoperable locally advanced, recurrent, or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Prematurely Ended) SE (Prematurely Ended) BE (Completed) DE (Prematurely Ended) HU (Completed) NL (Completed) IE (Prematurely Ended) AT (Prematurely Ended) PT (Prematurely Ended) FR (Completed) IT (Prematurely Ended) SK (Prematurely Ended) GR (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005721-55 Sponsor Protocol Number: CCR2638 Start Date*: 2007-04-23
    Sponsor Name:Imperial College Healthcare NHS Trust [...]
    1. Imperial College Healthcare NHS Trust
    2. Institute of Cancer Research
    Full Title: Adjuvant Cytotoxic Chemotherapy in Older Women
    Medical condition: Early breast cancer
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-006383-10 Sponsor Protocol Number: IEO S439/508 Start Date*: 2009-04-28
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: A phase II randomized study evaluating the role of 8 courses of primary chemotherapy versus 4 courses of primary chemotherapy in combination with endocrine therapy in locally advanced breast c...
    Medical condition: locally advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057654 Breast cancer female LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002346-33 Sponsor Protocol Number: MO43110 Start Date*: 2022-05-17
    Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
    Full Title: A PHASE IIIB, MULTINATIONAL, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE PATIENT PREFERENCE FOR HOME ADMINISTRATION OF FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB FOR SUBCUTANEOU...
    Medical condition: Early or locally advanced/inflammatory HER2-positive (HER2+) breast cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BG (Trial now transitioned) HR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-002678-21 Sponsor Protocol Number: APO-Peg-03 Start Date*: 2012-01-10
    Sponsor Name:Apotex Inc
    Full Title: A PHASE III, RANDOMIZED, ACTIVE CONTROLLED, ASSESSORBLINDED STUDY OF SAFETY AND EFFICACY OF PEGYLATED APOFILGRASTIM VERSUS US AND EU LICENSED NEULASTA® IN SUBJECTS WITH STAGE IIA, IIB OR IIIA BREA...
    Medical condition: Febrile neutropenia in breast cancer patients undergoing TAC chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10016288 Febrile neutropenia PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) CZ (Completed) BG (Completed) GR (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2016-005157-21 Sponsor Protocol Number: PH002-TP-II Start Date*: 2017-09-21
    Sponsor Name:Palleos healthcare GmbH
    Full Title: A prospective, randomized, multicenter, open-label comparison of pre-surgical combination of trastuzumab and pertuzumab with concurrent taxane chemotherapy or endocrine therapy given for twelve wee...
    Medical condition: Early HER2+/HR+ (triple positiveTP) breast cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000266-64 Sponsor Protocol Number: PEGF/USV/P3/003 Start Date*: 2015-06-18
    Sponsor Name:USV Limited
    Full Title: A Randomised, Multi-Centre, Assessor-Blinded, Active-Controlled, Parallel Group, Equivalence Phase III Study Comparing the Safety and Efficacy of USV Pegfilgrastim and Neulasta® in Breast Cancer Pa...
    Medical condition: Duration of Sever Neutropenia and incidence of febrile neutropenia
    Disease: Version SOC Term Classification Code Term Level
    18.0 10005329 - Blood and lymphatic system disorders 10029354 Neutropenia PT
    18.0 10005329 - Blood and lymphatic system disorders 10016288 Febrile neutropenia PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 06:35:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA